More interestingly was the fact that in the setting of stable disease after 6 cycles, those treated with maintenance cetuximab compared with no-maintenance showed a trend, although non-significant, for longer TTP of 9.2 vs. 6.6 ( p = 0.10), and OS of 19.8 vs. 7.7 ( p = 0.22).
← all excerpts
Molecular targeted agents for gastric cancer: a step forward towards personalized therapy.
1
—
—